Several protein toxins, including the A chain of the plant protein ricin (RTA), enter mammalian cells by endocytosis and catalytically modify cellular components to disrupt essential cellular processes. In the case of ricin, the process inhibited is protein synthesis. In order to reach their cytosolic substrates, several toxins undergo retrograde transport to the ER (endoplasmic reticulum) before translocating across the ER membrane. To achieve this export, these toxins exploit the ERAD (ER-associated protein degradation) pathway but must escape, at least in part, the normal degradative fate of ERAD substrates in order to intoxicate the cell. Toxins that translocate from the ER have an unusually low lysine content that reduces the likelihood of ubiquitination and ubiquitin-mediated proteasomal degradation. We have changed the two lysyl residues normally present in RTA to arginyl residues. Their replacement in RTA did not have a significant stabilizing effect on the protein, suggesting that the endogenous lysyl residues are not sites for ubiquitin attachment. However, when four additional lysyl residues were introduced into RTA in a way that did not compromise the activity, structure or stability of the toxin, degradation was significantly enhanced. Enhanced degradation resulted from ubiquitination that predisposed the toxin to proteasomal degradation. Treatment with the proteasomal inhibitor lactacystin increased the cytotoxicity of the lysine-enriched RTA to a level approaching that of wild-type RTA.
Introduction
Ricin is a member of the A-B family of plant and bacterial proteins that are potently toxic to mammalian cells [1] . These toxins consist of a catalytically active A polypeptide or fragment associated with one or more cell-binding B polypeptides. In the case of ricin the A polypeptide (RTA) catalyses the removal of a specific adenine residue from a highly conserved loop in 28 S rRNA. This adenine is crucial for the binding of elongation factors, and ribosomes containing RTA-modified 28 S rRNA are no longer able to synthesize protein. The B polypeptide of ricin (RTB) is a galactose-specific lectin that is responsible for binding ricin to cell-surface galacosides [2] . Cell binding is followed by the endocytic uptake of the toxin and its delivery into the endosomal system. A proportion of the ricin moves from early endosomes to the trans-Golgi network and from there to the ER (endoplasmic reticulum) lumen via the Golgi stack [3] . In the ER lumen RTA and RTB separate, a dissociation possibly mediated by protein disulphide isomerase, and RTA is transported across the ER membrane into the cytosol. It is now accepted that RTA and other toxins that translocate into the cytosol from the ER lumen exploit the normal quality control function of the ER in order to do so.
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ERAD (ER-associated protein degradation)
The quality-control system of the ER ensures that newly synthesized proteins fold into their native conformations and, if they are components of multimeric complexes, that they assemble correctly. Misfolded proteins or orphan subunits of oligomeric proteins are not retained by the cell but are proteolytically degraded [4] . This requires their export from the ER to the cytosol where they are degraded by the ubiquitin-proteasome system. This elimination of aberrant polypeptides is known as ERAD. RTA and the A chains of other toxins that translocate to the cytosol from the ER apparently masquerade as ERAD substrates in order to exploit the ERAD pathway for export. It was noted that all of these proteins have an unusually low lysine content, and it was proposed that this prevents ubiquitination, which predisposes proteins to proteasomal degradation, allowing them to subvert ERAD for entry into the cytosol [5] .
RTA exploits ERAD to retro-translocate from the ER
Experimental support for the contention that toxins exploit ERAD came from studies into the fate of RTA present in the ER lumen of tobacco and yeast cells [6, 7] . RTA with an N-terminal signal sequence was expressed in both cell types and shown, on the basis of signal sequence cleavage and the acquisition of N-linked oligosaccharide, to have co-translationally entered the ER lumen. Pulse-chase labelling showed that the ER-segregated RTA was proteolytically degraded. When RTA was expressed in yeast mutants defective either in proteasomal activity or in ER membrane translocation via the Sec61p translocon, the rate of proteolytic degradation was significantly reduced. The rate of RTA degradation was unaffected when its fate in yeast mutants defective in ubiquitination was compared with that in wildtype cells. Further, in tobacco cells the rate of RTA degradation was reduced in cells treated with proteasome inhibitors [8] . In both the yeast proteasome mutants and tobacco cells treated with proteasome inhibitors, the amount of N-glycosylated RTA decreased with a concomitant appearance of deglycosylated RTA, suggesting the glycosylated RTA was exported to the cytosol where it was deglycosylated by cytosolic peptide:N-glycanase [7, 8] .
A low lysine content to avoid ubiquitination
In the case of mammalian cells, treating them with the proteasomal inhibitor lactacystin sensitized them to ricin, suggesting the the low lysine content reduced but did not abolish proteasomal degradation of translocated RTA [9] . We confirmed that the two lysines naturally present in RTA were tolerated because they are not substrates for ubiquitination. When the two lysyl residues were changed to arginines the stability of RTA, as determined from the cytotoxicity of ricin holotoxin containing the RTA mutant, was indistinguishable from that of wild-type RTA [10] . However, when four additional lysines were introduced into RTA in a way that did not compromise the activity, structure or stability of the toxin, degradation was significantly enhanced. The RTA residues selected for substitution with lysines were chosen following a detailed structural comparison of RTA with a closely related protein that does not enter the cytosol from the ER lumen. PAP (pokeweed antiviral protein) is a singlechain member of the ribosome-inactivating protein family that is structurally homologous with RTA. Unlike ricin, PAP does not have a cell-binding B chain and is therefore unable to enter cells with the same efficiency. In marked contrast with RTA, PAP contains a total of 20 lysines. The X-ray structures of both RTA and PAP have been determined and are essentially superimposable, allowing surface residues of RTA to be substituted with lysines at positions where lysines are naturally present in PAP. Ricin containing RTA enriched in lysyl residues was ≈100-fold less cytotoxic than ricin containing wild-type RTA. This reduction in cytotoxicity was not due to the introduction of four residues with positively charged side chains: the introduction of four arginine residues in place of the four lysines was essentially without effect on cytotoxicity. Rather, it was due to an enhanced rate of degradation of the toxin in the cytosol. Enhanced degradation resulted from ubiquitination that predisposed the toxin to proteasomal proteolysis. Treatment with the proteasomal inhibitor lactacystin increased the cytotoxicity of ricin containing lysine-rich RTA to a level approaching that of wild-type ricin [10] . The addition of four extra lysyl residues into a second toxin believed to translocate from the ER, abrin A chain, also dramatically decreased the cytotoxicity of the holotoxin compared with wild-type abrin. The same conclusions were reached in a separate study that focused on a bacterial toxin known to translocate from the ER, cholera toxin A1 chain [11] . A cholera toxin A1 mutant that lacked lysines and had a blocked N-terminus, and therefore could not be ubiquitinated, remained active in vivo. The A1 chain did not appear to be degraded in the cytosol, since treatment with proteasome inhibitors did not sensitize cells to the toxin. In this respect cholera toxin A1 differs from RTA, probably because it refolds much more rapidly than RTA. The introduction of additional lysyl residues into cholera toxin A1 also reduced its activity, and the activity of the lysine-rich A1 was restored to wild-type levels in the presence of proteasome inhibitor.
How is RTA perceived as an ERAD substrate by the cell?
RTA must partially unfold in order to become translocationally competent [12] . If this unfolding occurs in the ER lumen, misfolded RTA would become an ERAD substrate, making its export from the ER inevitable. We have observed that the binding of RTA to negatively charged phospholipid vesicles leads to protein unfolding and a destabilization of the lipid bilayer [13] . Although these data were obtained for the interaction of RTA with lipid vesicles in vitro, it is possible to speculate on the potential outcome of an RTAlipid interaction in vivo. Upon reaching the ER by retrograde transport through the secretory pathway, RTA and RTB might be separated by protein disulphide isomerase-mediated reduction of the interchain disulphide bond. The released RTA might then interact with negatively charged lipids in the ER membrane, and the partially unfolded RTA would present as an ERAD substrate, leading to its export to the cytosol.
Native RTA is extremely resistant to proteolytic degradation, whereas partially unfolded RTA is much more sensitive [14] . Partially unfolded RTA entering the cytosol would thus be susceptible to proteasomal degradation, and it seems clear that a substantial proportion of the translocated toxin is destroyed at this stage [9] . How does a proportion of the toxin avoid degradation? We have shown that partially unfolded RTA refolds in the presence of ribosomes, regaining full catalytic activity [15] . It seems likely that some of the newly translocated RTA interacts with ribosomes rather than proteasomes, and this interaction results in RTA refolding which renders the protein resistant to proteolysis. The ribosome pays the ultimate price for this refolding role, since restoration of the toxin to its biologically active conformation results in 28 S rRNA depurination. Chaperoning RTA refolding is a suicidal act for the ribosome.
Conclusion
Collectively, the data described in brief above support the hypothesis that the evolution of a low lysine content is a degradation-avoidance strategy adopted by toxins that translocate from the ER by subverting ERAD. The experimental data supporting this contention are published in detail elsewhere [10, 11] .
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